Human antibodies to bacterial polyaaccharides consist primarily of IgG and are largely restricted to the IgG2 subclass. We examined the ontogeny of the IgG subclass response to pneumococcal ...

Please provide your email address to receive an email when new articles are posted on . Herd immunity generated by the introduction of the 13-valent pneumococcal conjugate vaccine in the United States ...

Pneumococcal vaccines, including pneumococcal polysaccharide vaccine (PPV) and pneumococcal conjugated vaccine (PCV), are crucial in preventing invasive pneumococcal diseases. We analyzed the ...

The FDA approved a 21-valent pneumococcal conjugate vaccine (Capvaxive) for preventing invasive pneumococcal disease and pneumococcal pneumonia in adults, Merck announced on Monday. Specifically ...

Pneumococcal polysaccharide conjugate vaccines prevent pneumococcal disease in infants, but their efficacy against pneumococcal community-acquired pneumonia in adults 65 years of age or older is ...

The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive (pneumococcal polysaccharide conjugate vaccine [21-valent]) intended to ...

Please provide your email address to receive an email when new articles are posted on . To avoid uncertainty, an expert recommends physicians understand each vaccine’s serotypes and which ones are ...

To improve diagnostic options for pneumococcal pneumonia, an ELISA system was developed that can detect ⩽6 ng/ml capsular polysaccharide in serum. The test was limited to 39 serotypes causing >95% of ...